Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EU Notified Bodies Prepare For En Masse Redesignation

Executive Summary

Members of the TEAM-NB association, which account for about half of the anticipated future force of EU medtech notified bodies, are taking a coordinated approach to applying for redesignations against the new EU Medical Device and IVD Regulations. Will they succeed?

You may also be interested in...



EU Implementation Plan For New Regs Starts To Take Shape

The European Commission and competent authorities are now putting together an implementation roadmap that will change the face of medical device and IVD oversight across the region. Medtech industry representatives and other stakeholders weighed in on priorities during a March 9 meeting. More details on the implementation roadmap for the Medical Device and IVD Regulations can be expected in June.

Comply With EU MDD Or MDR? Your Multi-Year Decision Is Beset With Hazards

Will it be better to continue compliance under the Medical Devices Directive or switch to compliance under the new Medical Devices Regulation when there is a choice? The pros and cons make it a difficult decision.

Interim Eudamed Scheme: Early SRN Access To Aid Voluntary Actor Registration

The new Eudamed database may be delayed for two years, but the European Commission wants to allow early access to Single Registration Numbers before Eudamed goes live in 2022 to aid voluntary registration in the interim.

Topics

UsernamePublicRestriction

Register

MT104485

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel